Answers are grounded in this paper and cite their sources.
Background. Vulvar cancer remains a rare but aggressive pathology with a high percentage of advanced cases at the time of diagnosis. Understanding the role of the tumor microenvironment is critically important for predicting disease progression and developing new therapeutic strategies. Aim. To evaluate the prognostic significance of expression of stemness (ALDH1, CD133), matrix remodeling (MMP-2, TIMP-2) and immunosuppression (CD68, CD206, FoxP3) markers in tumor cells and stroma of vulvar squamous cell carcinoma. Materials and methods. A retrospective immunohistochemical study was conducted on surgical specimens from 56 patients with confirmed vulvar squamous cell carcinoma (stage I: n = 20; stage II: n = 26; recurrences: n = 10). A semi-quantitative analysis of marker expression was performed, assessing associations with clinical and morphological parameters (stage, invasion depth). Results. Vulvar cancer progression (stage II, invasion 4 mm) was associated with an increase in the stem cell pool (ALDH1+ in the stroma, CD133+ in the tumor); an increase in MMP-2 expression (p = 0.01); accumulation of M2 macrophages (CD206+) and regulatory T cells (FoxP3+) in the stroma, with levels 4 times higher than in the parenchyma. Recurrences were characterized by a profile similar to early stages but with dominance of the M2 phenotype in the stroma ( 50 %) and a higher level of CD133+ expression. Conclusion. Stroma-dependent immunosuppression and stem cell activation are key drivers of vulvar cancer progression. The findings support the potential of targeted therapy directed at tumor microenvironment components.
No takes yet. Share an insight, caveat, or question.
Abdullaeva et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: